Amphiphilic Peptide Micelles for Soluble Antigen Nanoparticle Vaccines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines, particularly those targeting water-soluble antigens, face challenges in antibody production efficiency, stability, and safety, especially for viruses like dengue fever where cross-reactivity can lead to increased infection risk due to weak antibody binding.
Innovation Solution
Development of nanoparticles composed of amphiphilic peptides forming micelles that self-assemble and bind target peptides, allowing precise targeting of antigen-presenting cells without chemical modification, using small peptides to enhance antibody production and minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If water-soluble antigens are used as vaccines, then the vaccine can be administered easily and is safe, but antibody production efficiency is significantly lower compared to particulate antigens
Solution Approach 1:
The patent changes the physical state parameter of the antigen from soluble to particulate by forming micelles. The amphiphilic peptide self-assembles into micellar structures that present the water-soluble antigen in a particulate form, thereby enhancing immunogenicity and antibody production efficiency while maintaining the advantages of water-soluble antigens
Solution Approach 2:
The patent creates a composite structure where the amphiphilic peptide forms a micellar carrier that encapsulates or presents the water-soluble antigen. This composite micellar system combines the benefits of particulate antigens (high immunogenicity) with the advantages of water-soluble antigens (ease of administration and safety)
2Productivity
If traditional adjuvants are used to enhance antibody production, then immunogenicity is improved, but toxicity and safety issues arise
Solution Approach 1:
The amphiphilic peptide micelle acts as an intermediary carrier that presents the antigen in a particulate form without requiring traditional adjuvants. The micelle structure itself provides the necessary immunogenic enhancement, eliminating the need for separate adjuvant components that would introduce toxicity and safety concerns
3Manufacturing precision
If haptens are used to produce antibodies, then specific antibody production is achieved, but accessibility problems and structural changes occur
Solution Approach 1:
The patent extracts the antigenic determinant from the water-soluble antigen and presents it on the surface of the amphiphilic peptide micelle. This allows the antigen to be recognized by the immune system in its native conformation without requiring chemical modification or coupling to carrier proteins, thereby avoiding accessibility problems and unwanted structural changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles effectively induce targeted immune responses, increasing antibody production and reducing side effects by precise antigen presentation, suitable for multivalent vaccines against diseases such as dengue fever and influenza.
Implementation Method 1
an amphiphilic peptide that forms a micelle structure by self-assembly
Implementation Method 2
micelle structure which is composed of an amphiphilic peptide
Implementation Method 3
a target peptide that electrically binds to a surface of the amphiphilic peptide
Data Source
AI summary
A nanoparticle and a preparation method therefor, the nanoparticle including an amphiphilic peptide, which forms a micelle structure through self-assembly, and a target peptide (preferably, a water-soluble antigen peptide), which electrically binds to the surface of the amphiphilic peptide. The target peptide electrically binds to the surface of the amphiphilic peptide micelle structure and becomes particulated, and thus can be effectively presented to an antigen-presenting cell, and the weight ratio of the amphiphilic peptide and the target peptide is controlled so that the size of nanoparticles is controlled and endocytosis thereof is carried out, and thus immunity by means of cytotoxic T cells can be induced. Nanoparticles exhibit use only an epitope of a more accurate region so as to be effective as a vaccine, and thus have minimal side effects. Therefore, excellent antigen-specific antibody and cell immunotherapy effects are exhibited, and thus can be used in various fields such as vaccine production.